NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)


RTOG-1216:  ORAL CAVITY, OROPHARYNX, LARYNX, or HYPOPHARYNX, Squamous Stg III-IV, M0, post-total resection; RT + concurrent Cisplatin or Docetaxel or Docetaxel & Cetuximab (IMRT credentialing is required – see protocol.)

Effective 2-22-16



NRG-GY005:  Ovarian, peritoneal, or fallopian tube, serous or endometrioid ca,recurrent platinum-resistant. Non platinum based std chemo vs Cediranib/Olaparib vs Cediranib alone vs Olaparib alone


Effective 6-16-17


ECOG-ACRIN EA6141:  Melanoma, unresectable stage III or stage IV, Nivolumab + Ipilimumab + or - Sargramostim (GM-CSF)


Effective 6-23-17


NRG CC003:  PCI w/wo hippocampal avoidance, small cell lung cancer, neurocognitive assessment (IMRT credentialing required)

Effective 10-13-17


SWOG S1318:  ALL, new dx, ≥ 65 years old.  Philadelphia negative:  Blinatumomab/POMP.  Philadelphia positive:  Dasatinib/Prednisone/Blinatumomab.  Cohort 2

Effective 9-28-17


Alliance A021501:  Head of pancreas, borderline resectable, T1-4, N0-1, Nx, M0, neo adjuvant chemo vs neo adjuvant chemo + RT.

Effective 5-9-18


Alliance A091401:  Stage IV or unresectable, measurable sarcoma, ≥ 1 prior systemic therapy, nivolumab vs. nivolumab + ipilimumab,

Effective 9-5-18


ARST1321:  Soft tissue sarcoma of extremity or trunk, newly diagnosed, neoadjuvant, chemo + RT vs RT +/- Pazopanib.

Effective 10-1-18





































  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA